John Walter Hanna Jr., who serves as President and Chief Executive Officer at CareDx, Inc. (NASDAQ: CDNA), executed the sale of 19,480 shares of common stock on January 21 and 22, 2026, as detailed in a recent Securities and Exchange Commission filing. These dispositions yielded total gross proceeds of approximately $412,222.
The transactions were carried out at varying prices over two consecutive trading days. On January 21, Hanna sold 200 shares at a fixed price of $21 per share. Subsequent sales on January 22 involved multiple transactions summing to 19,280 shares, with prices fluctuating between $21.00 and $21.43 per share.
Following these transactions, Hanna continues to hold a substantial equity interest in CareDx, directly owning 597,405 shares. The share sales were executed under a Rule 10b5-1 trading plan which Hanna adopted on December 13, 2024, allowing for scheduled transactions irrespective of nonpublic information.
In parallel with these insider sales, CareDx disclosed a favorable financial performance for the fourth quarter of 2025, reporting revenue of roughly $108 million, marking a 25% increase compared with the prior year’s period. Furthermore, the company projects full-year 2025 revenues to reach near $380 million, translating to an approximate 14% annual growth rate.
CareDx’s core testing services business contributed significantly to this growth, generating about $78 million in revenue during the fourth quarter, up 23% year-over-year. The company additionally announced a collaborative venture with 10x Genomics, establishing a new research initiative named ImmuneScape. This partnership aims to employ advanced technological platforms to investigate mechanisms of transplant organ rejection at a cellular level.
On the market perception front, Craig-Hallum has recently downgraded CareDx’s shares from a Buy to a Hold rating, citing a less attractive risk-reward outlook. Despite this, CareDx has released data indicating its HeartCare molecular testing platform’s capability to help identify heart transplant recipients at a higher risk of developing complications.
Moreover, CareDx surpassed revenue estimates in the third quarter of 2025, reporting $100.1 million against the anticipated $95.32 million, with earnings per share that considerably exceeded analysts’ expectations.